Here’s the introduction to their piece.. anybody following the market will know that FDA approval is pending and the company are very active in medical states around the US
Why Marijuana Stock GW Pharmaceuticals Gained 21% in May
GW Pharmaceuticals (NASDAQ:GWPH) jumped 21.1% in May, according to data provided by S&P Global Market Intelligence. While there didn’t seem to be much news for the marijuana drug company last month, the increased valuation is likely tied to investors who jumped in ahead of a Food and Drug Administration (FDA) decision on GW Pharmaceuticals’ epilepsy drug Epidiolex, which is due later this month.
The FDA is scheduled to make a decision on or before June 27 about Epidiolex as a treatment for two rare forms of epilepsy called Dravet syndrome and Lennox-Gastaut syndrome. That date is only a goal, so the decision could come earlier — or even later, although the FDA has been generally on time these days.
After a positive FDA advisory committee meeting, an approval seems likely. Technically, the agency isn’t required to follow the recommendation of its outside advisers, but given the ringing endorsement and the unmet medical need for patients with Dravet syndrome and Lennox-Gastaut syndrome, an approval seems likely.